Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724058 | 1.00 | MAPT (0.49) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL15308687 | 0.89 | MEN1 (0.43) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL4221 | 0.85 | — | — | |
| SCHEMBL237380 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL2375356 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL8891623 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL26115526 | 0.84 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28788727 | 0.83 | — | — | |
| SCHEMBL13044831 | 0.83 | MAPT (0.47) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL7894571 | 0.83 | MAPT (0.47) | MAPTALDH1A1KMT2AMEN1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192064-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-2787992-B1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-9073853-B2 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| US-9073853-B2 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20140288106-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140288106-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| WO-2013084013-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-06-13 | — | — | WO | disclosed |
| EP-2601950-A1 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2013-06-12 | — | — | EP | disclosed |
| EP-2601950-A1 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2013-06-12 | — | — | EP | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-6337034-B1 | COMPOUNDS HAVING WIDE TEMPERATURE RANGE OF LIQUID CRYSTAL PHASE, LOW VISCOSITY, LOW THRESHOLD VOLTAGE AND EXCELLENT STABILITY, WHICH ARE READILY MIXED WITH VARIOUS LIQUID CRYSTAL MATERIALS AND GOOD IN SOLUBILITY AT LOW TEMPERATURE | CHISSO CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-0885875-A1 | VINYLENE COMPOUNDS AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | MAPT 3382/4885ALDH1A1 1257/4885KMT2A 2905/4885 |
| US-20140288106-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CCR5 | MAPT 4806/4885ALDH1A1 995/4885KMT2A 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.